ES2582306T3 - Derivados de morfinano que contienen un grupo carboxamida como ligandos de receptores opioides - Google Patents
Derivados de morfinano que contienen un grupo carboxamida como ligandos de receptores opioidesInfo
- Publication number
- ES2582306T3 ES2582306T3 ES11715100.1T ES11715100T ES2582306T3 ES 2582306 T3 ES2582306 T3 ES 2582306T3 ES 11715100 T ES11715100 T ES 11715100T ES 2582306 T3 ES2582306 T3 ES 2582306T3
- Authority
- ES
- Spain
- Prior art keywords
- optionally substituted
- alkyl
- hydrogen
- conr10
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/22—Bridged ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/22—Bridged ring systems
- C07D221/26—Benzomorphans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/22—Bridged ring systems
- C07D221/28—Morphinans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
- C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
- C07D489/08—Oxygen atom
Abstract
Compuesto de fórmula I: **Fórmula** donde R1 se selecciona entre -OH, -CN, -CHO, -COR10, -COOR10, -SO2R10, -CONH2, -CSNH2, - CONR10((C(R12)(R13))tCO-NR10R11, -CONR10((C(R12)(R13))tCOOR11, -C(>=S)R10 y -C(>=NR10)R11; R2 se selecciona entre hidrógeno, halógeno, -OH, -CN, -CHO, -OCH3, -OCH2CH3, -OCH(CH3)2, - NO2, -COR10, -COOR10, -SO2R10, -CONR10R11, -CSNR10R11, -CONR10NR11R12, -CONR10OR11, -CONR10((C(R12)(R13))tCONR10R11, -CONR10((C(R12)(R13))tCOOR11, -C(>=S)R10, -C(>=NOR11)R10, - C(>=NR10)R11, -SO2NR10R11, heterociclilo, alquilo(C1-C6) opcionalmente sustituido, alquenilo opcionalmente sustituido, alquinilo opcionalmente sustituido, arilo opcionalmente sustituido, haloalquilo(C1-C6), haloalcoxi(C1-C6), y alquiltio(C1-C6); o, R1 y R2, junto con los átomos a los que están unidos y un fragmento seleccionado entre -OCH2O-y - OCH2CH2O-, forman un anillo; R3 se selecciona entre hidrógeno, hidrocarburo(C1-C8), heterociclilo, arilo e hidroxialquilo; R4 se selecciona entre hidrógeno, hidroxilo, amino, alcoxi(C1-C4), alquilo(C1-C20) y alquilo(C1-C20) sustituido con hidroxilo o carbonilo; R5 es alquilo(C1-C6); R6 es alquilo(C1-C6); R7 se selecciona entre hidrógeno, NR10R11 y -OR10; o R4, R5, R6 y R7 juntos pueden formar uno, dos, tres o cuatro anillos, teniendo dichos anillos una sustitución adicional opcional; R8 y R8a son ambos hidrógeno, o R8 y R8a juntos son >=O; R9 se selecciona entre hidrógeno y alquilo(C1-C6); R10, R11, R12 y R13 son, independientemente en cada caso, hidrógeno, alquilo(C1-C6) opcionalmente sustituido, alquenilo opcionalmente sustituido, alquinilo opcionalmente sustituido, arilo opcionalmente sustituido, hidroxilo, -NR100R101 o alcoxi(C1-C4) opcionalmente sustituido, o R10 y R11, junto con el átomo de nitrógeno al que están unidos, forman un anillo heterocíclico o carbocíclico fusionado opcionalmente sustituido, de 5 a 7 miembros de anillo, de los cuales hasta 3 pueden ser heteroátomos seleccionados entre N, O y S; t es 0, 1, 2, 3, 4, 5 o 6;
Claims (1)
- ---
imagen1 imagen2 imagen3 imagen4 imagen5 imagen6 imagen7 imagen8 imagen9 imagen10 imagen11 imagen12 imagen13
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31617510P | 2010-03-22 | 2010-03-22 | |
US316175P | 2010-03-22 | ||
US39414810P | 2010-10-18 | 2010-10-18 | |
US394148P | 2010-10-18 | ||
US42191510P | 2010-12-10 | 2010-12-10 | |
US421915P | 2010-12-10 | ||
PCT/US2011/029425 WO2011119605A2 (en) | 2010-03-22 | 2011-03-22 | Carboxamide biosiosteres of opiates |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2582306T3 true ES2582306T3 (es) | 2016-09-12 |
Family
ID=44072680
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES11715100.1T Active ES2582306T3 (es) | 2010-03-22 | 2011-03-22 | Derivados de morfinano que contienen un grupo carboxamida como ligandos de receptores opioides |
Country Status (8)
Country | Link |
---|---|
US (4) | US8436175B2 (es) |
EP (1) | EP2550253B9 (es) |
JP (2) | JP5964809B2 (es) |
AU (1) | AU2011232628B2 (es) |
CA (1) | CA2793725C (es) |
ES (1) | ES2582306T3 (es) |
HK (1) | HK1181045A1 (es) |
WO (1) | WO2011119605A2 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7557119B2 (en) | 2005-07-21 | 2009-07-07 | Rensselaer Polytechnic Institute | Large substituent, non-phenolic opioids |
EP3569234A1 (en) | 2009-12-04 | 2019-11-20 | Alkermes Pharma Ireland Limited | Morphinan derivatives for the treatment of drug overdose |
JP5964809B2 (ja) | 2010-03-22 | 2016-08-03 | レンセラール ポリテクニック インスティチュート | オピオイド受容体リガンドとしてのカルボキサミド基を含有するモルヒネ誘導体 |
HUE041981T2 (hu) | 2010-08-23 | 2019-06-28 | Alkermes Pharma Ireland Ltd | Eljárások antipszichotikum által kiváltott súlygyarapodás kezelésére |
HUE034326T2 (en) * | 2011-06-29 | 2018-02-28 | Alkermes Inc | Peripheral acting opioid compounds |
US9211293B2 (en) | 2011-12-15 | 2015-12-15 | Alkermes Pharma Ireland Limited | Opioid agonist antagonist combinations |
EP3004114B1 (en) | 2013-05-24 | 2019-12-25 | Alkermes Pharma Ireland Limited | Morphan and morphinan analogues, and methods of use |
WO2014190271A2 (en) | 2013-05-24 | 2014-11-27 | Alkermes Pharma Ireland Limted | Methods for treating depressive symptoms |
CN103992272B (zh) * | 2014-06-09 | 2016-05-11 | 安徽省逸欣铭医药科技有限公司 | 一种盐酸喷他佐辛酯、其制备方法及其用途 |
WO2022101444A1 (en) | 2020-11-12 | 2022-05-19 | Alkermes Pharma Ireland Limited | Immediate release multilayer tablet |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES252980A1 (es) | 1958-10-30 | 1960-11-01 | Boehringer Sohn Ingelheim | Procedimiento para la obtencion de nuevas sales cuaternarias, terapéuticamente valiosas, de la normorfina y de sus derivados |
CH581624A5 (es) | 1970-08-14 | 1976-11-15 | Sumitomo Chemical Co | |
US3856795A (en) | 1972-04-25 | 1974-12-24 | American Home Prod | Process for preparation of secondary amines from tertiary amines |
DE2254298A1 (de) | 1972-11-06 | 1974-05-16 | Boehringer Sohn Ingelheim | Neue (heteroarylmethyl)-normorphine, deren saeureadditionssalze, verfahren zu deren herstellung sowie deren verwendung als arzneimittel |
US4032529A (en) | 1974-09-20 | 1977-06-28 | Sterling Drug Inc. | Aminomethanobenzazocine intermediates |
US3957793A (en) | 1974-09-20 | 1976-05-18 | Sterling Drug Inc. | Hydroxyiminobenzazocines |
US4205171A (en) | 1976-01-12 | 1980-05-27 | Sterling Drug Inc. | Aminomethanobenzazocines and nitromethanobenzazocines |
US4176186A (en) | 1978-07-28 | 1979-11-27 | Boehringer Ingelheim Gmbh | Quaternary derivatives of noroxymorphone which relieve intestinal immobility |
US4373139A (en) | 1979-04-30 | 1983-02-08 | Motorola, Inc. | Detectors |
FR2514644A1 (fr) | 1981-10-19 | 1983-04-22 | Sanofi Sa | Composition pharmaceutique a action antagoniste peripherique des opiaces |
US4374139A (en) | 1981-11-09 | 1983-02-15 | Hoffmann-La Roche Inc. | Levorotatory N-substituted acylmorphinans useful as analgesic agents |
US4649200A (en) | 1986-05-08 | 1987-03-10 | Regents Of The University Of Minnesota | Substituted pyrroles with opioid receptor activity |
US4939264A (en) | 1986-07-14 | 1990-07-03 | Abbott Laboratories | Immunoassay for opiate alkaloids and their metabolites; tracers, immunogens and antibodies |
US4929622A (en) | 1987-09-24 | 1990-05-29 | Hoechst-Roussel Pharmaceuticals, Inc. | 2,6-Methanopyrrolo-3-benzazocines |
US5258386A (en) | 1991-06-05 | 1993-11-02 | The United States Of America As Represented By The Secretary Of The Army | (+)-3-substituted-N alkylmorphinans, synthesis and use as anticonvulsant and neuroprotective agents |
US5607941A (en) | 1992-06-26 | 1997-03-04 | Boehringer Ingelheim Kg | Useful for treating neurodegenerative diseases |
SE9103745D0 (sv) | 1991-12-18 | 1991-12-18 | Wikstroem Haakan | Aryl-triflates and related compounds |
EP0632041A1 (en) | 1993-07-01 | 1995-01-04 | Katholieke Universiteit Nijmegen | New morphine derivatives having improved analgesic and narcotic properties |
US6365594B1 (en) | 1996-01-10 | 2002-04-02 | Smithkline Beecham S.P.A. | Heterocycle-condensed morphinoid derivatives (II) |
ES2121553B1 (es) | 1996-12-23 | 1999-06-16 | Univ Santiago Compostela | Nuevos endoperoxidos morfinicos funcionalizados en posiciones c-6 y c-14 del anillo c y procedimiento para su obtencion. |
GB9709972D0 (en) | 1997-05-19 | 1997-07-09 | Pfizer Ltd | Tetrazoles |
GB9912411D0 (en) | 1999-05-28 | 1999-07-28 | Pfizer Ltd | Compounds useful in therapy |
WO2001012197A1 (en) | 1999-08-13 | 2001-02-22 | Southern Research Institute | Pyridomorphinans, thienomoprhinans and use thereof |
ES2278647T3 (es) | 1999-11-29 | 2007-08-16 | Adolor Corporation | Nuevos procedimientos y composiciones que comprenden opioides y antagonistas de opioides. |
AU2002227135B2 (en) | 2000-10-31 | 2008-01-03 | Rensselaer Polytechnic Institute | 8- substituted-2, 6-methano-3-benzazocines and 3-substituted morphinanes as opioid receptor binding agents |
US7375082B2 (en) | 2002-02-22 | 2008-05-20 | Shire Llc | Abuse-resistant hydrocodone compounds |
US20050222204A1 (en) | 2002-05-30 | 2005-10-06 | Mitch Charles H | Opioid receptor antagonists |
DE10228103A1 (de) | 2002-06-24 | 2004-01-15 | Bayer Cropscience Ag | Fungizide Wirkstoffkombinationen |
DE10229842A1 (de) | 2002-07-03 | 2004-02-05 | Helmut Prof. Dr. Schmidhammer | Morphinanderivate und deren quartäre Ammoniumsalze substituiert in Position 14, Herstellungsverfahren und Verwendung |
AU2003281060A1 (en) | 2002-07-16 | 2004-02-02 | Rensselaer Polytechnic Institute | Process for conversion of phenols to carboxamides via the succinimide esters |
US7271173B2 (en) | 2002-11-18 | 2007-09-18 | The Mclean Hospital Corporation | Mixed kappa/mu opioids and uses thereof |
WO2006000020A1 (en) | 2004-06-29 | 2006-01-05 | European Nickel Plc | Improved leaching of base metals |
WO2006052710A1 (en) | 2004-11-05 | 2006-05-18 | Rensselaer Polytechnic Institute | 4-hydroxybenzomorphans |
EP1820795A4 (en) * | 2004-12-07 | 2010-10-20 | Toyama Chemical Co Ltd | NEW ANTHRANILIC ACID DERIVATIVE OR SALT FROM IT |
EP1861096B1 (en) | 2005-03-07 | 2018-12-26 | The University of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
BRPI0611707A2 (pt) | 2005-06-29 | 2012-04-24 | Compumedics Ltd | conjunto de sensor com ponte condutiva |
US7557119B2 (en) | 2005-07-21 | 2009-07-07 | Rensselaer Polytechnic Institute | Large substituent, non-phenolic opioids |
EP1928881A2 (en) | 2005-08-19 | 2008-06-11 | Pharmacofore, Inc. | Prodrugs of active agents |
TW200801513A (en) | 2006-06-29 | 2008-01-01 | Fermiscan Australia Pty Ltd | Improved process |
CA2686851A1 (en) | 2007-05-16 | 2008-11-27 | Rensselaer Polytechnic Institute | Fused-ring heterocycle opioids |
CN101827819B (zh) * | 2007-08-09 | 2013-06-12 | 伦斯勒理工学院 | 阿片样物质酰胺季铵盐 |
WO2010000020A1 (en) | 2008-06-30 | 2010-01-07 | Cathrx Ltd | A catheter |
AU2009274147B2 (en) | 2008-07-21 | 2014-09-04 | Rensselaer Polytechnic Institute | Large substituent, non-phenolic amine opioids |
WO2011000020A1 (en) | 2009-06-12 | 2011-01-06 | Sbc Research Pty Ltd | Enhanced method of detection |
JP5964809B2 (ja) | 2010-03-22 | 2016-08-03 | レンセラール ポリテクニック インスティチュート | オピオイド受容体リガンドとしてのカルボキサミド基を含有するモルヒネ誘導体 |
-
2011
- 2011-03-22 JP JP2013501397A patent/JP5964809B2/ja active Active
- 2011-03-22 CA CA2793725A patent/CA2793725C/en active Active
- 2011-03-22 AU AU2011232628A patent/AU2011232628B2/en active Active
- 2011-03-22 EP EP11715100.1A patent/EP2550253B9/en active Active
- 2011-03-22 US US13/069,104 patent/US8436175B2/en active Active
- 2011-03-22 ES ES11715100.1T patent/ES2582306T3/es active Active
- 2011-03-22 WO PCT/US2011/029425 patent/WO2011119605A2/en active Application Filing
-
2013
- 2013-04-05 US US13/857,588 patent/US8716306B2/en active Active
- 2013-07-15 HK HK13108291.4A patent/HK1181045A1/zh unknown
-
2014
- 2014-03-12 US US14/206,170 patent/US8957085B2/en active Active
-
2015
- 2015-01-05 US US14/589,164 patent/US9422301B2/en active Active
-
2016
- 2016-04-08 JP JP2016078368A patent/JP2016175910A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP2550253B1 (en) | 2016-04-27 |
US20110230511A1 (en) | 2011-09-22 |
EP2550253A2 (en) | 2013-01-30 |
US20140194457A1 (en) | 2014-07-10 |
JP2016175910A (ja) | 2016-10-06 |
US20130225628A1 (en) | 2013-08-29 |
HK1181045A1 (zh) | 2013-11-01 |
CA2793725A1 (en) | 2011-09-29 |
CA2793725C (en) | 2018-05-01 |
US8957085B2 (en) | 2015-02-17 |
US8436175B2 (en) | 2013-05-07 |
AU2011232628A1 (en) | 2012-10-18 |
JP5964809B2 (ja) | 2016-08-03 |
US8716306B2 (en) | 2014-05-06 |
EP2550253B9 (en) | 2016-09-21 |
WO2011119605A3 (en) | 2011-11-17 |
US20150119416A1 (en) | 2015-04-30 |
US9422301B2 (en) | 2016-08-23 |
WO2011119605A2 (en) | 2011-09-29 |
JP2013522368A (ja) | 2013-06-13 |
AU2011232628B2 (en) | 2015-04-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2582306T3 (es) | Derivados de morfinano que contienen un grupo carboxamida como ligandos de receptores opioides | |
ES2521596T3 (es) | Combinación del compuesto GlyT1 con antipsicóticos | |
AR080187A1 (es) | Derivados pirazolicos condensados con heterociclos nitrogenados utiles en el tratamiento de enfermedades inflamatorias, inmunitarias y/o trastornos mieloploliferativos y composiciones farmaceuticas que los contienen. | |
ES2669189T3 (es) | Compuestos de carbazol útiles como inhibidores del bromodominio | |
AR098666A1 (es) | Compuestos de biarilacetamida y sus métodos de uso | |
AR093404A1 (es) | Compuestos macrociclicos que modulan la actividad de los inhibidores de la apoptosis | |
AR055592A1 (es) | Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace) | |
AR077292A1 (es) | Derivados de piperazin - quinolin sulfonamidas y composiciones farmaceuticas | |
AR081426A1 (es) | Derivados de pirazol inhibidores del receptor sigma | |
PE20181024A1 (es) | Derivados de ciclohexano sustituido con amido | |
AR095311A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante | |
AR104208A1 (es) | Compuestos bicíclicos como inhibidores de autotaxina (atx) | |
AR081932A1 (es) | Derivados de heteroaril imidazolona, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades neoplasicas y autoinmunes | |
AR091279A1 (es) | Inhibidores macrociclicos de virus flaviviridae | |
CO5680412A2 (es) | Agonistas del receptor adrenergico etilamino beta 2 sustituido con amino | |
AR089568A1 (es) | Compuestos heterociclicos y sus metodos de usos | |
PE20190653A1 (es) | Nuevos derivados de pirrol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
AR066153A1 (es) | Derivados de piperidina / piperazina | |
AR085283A1 (es) | Antagonistas de hepcidina a base de sulfonaminoquinolina | |
AR088829A1 (es) | DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3 | |
AR067613A1 (es) | Inhibidores de adn-pk, uso y sintesis de los mismos | |
AR082889A1 (es) | Compuestos y composiciones para la inhibicion de nampt | |
AR093184A1 (es) | Compuesto de pirimidina sustituida como inhibidor de quinurenina-3-monooxigenasa y composicion farmaceutica que lo comprenden | |
AR094762A1 (es) | Compuestos de hexahidropirano[3,4-d][1,3]tiazin-2-amina sustituida con heteroarilo | |
AR060621A1 (es) | Compuestos triarilicos y sus derivados |